Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Iveric Bio
Annexon’s ANX007 Misses GA Endpoint, But May Have Visual Acuity Path Forward
The ARCHER study did not show improvement in lesion growth, but still showed an improvement in best corrected visual acuity, potentially opening a pathway toward a pivotal trial.
Allure Of Apellis Enhanced By Stellar Launch Of Syfovre
Rival Iveric may be in the process of being bought by Astellas but that has done nothing to dampen interest in Apellis and its geographic atrophy treatment Syfovre which was only launched in March yet reached Q1 sales of over $18m.
Astellas Paying $5.9bn For Iveric To Boost Ophthalmology Presence
Astellas set to acquire private US firm to add to its strategic capabilities in ophthalmology focus area, along with another revenue pillar as it prepares for Xtandi expiry.
Germany’s Complement Bets On Gene Therapy For Geographic Atrophy
US approval of Apellis's Syfovre has validated the complement approach for treating the advanced stage of age-related macular degeneration but a Munich-headquartered start-up believes its gene therapy will be a more potent and less burdensome alternative.
- Antisense, Oligonucleotides
- Gene Therapy, Cell Therapy
- Large Molecule
- Other Names / Subsidiaries
- Inception 4, Inc.
- Ophthotech Corporation (OPHT)
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.